Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)

Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)

Disclosed is humanized antibody or fragment thereof capable of binding to interleukin-l0 (IL-10), wherein said antibody or fragment thereof comprises a variable light chain comprising the amino acid sequences of CDR 1, CDR2 and CDR3 of the murine antibody B-NI0 variable light chain, and a variable h...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: DAELKEN BENJAMIN, ROTTGEN PETER, UHEREK CHRISTOPH, CZELOTH NIKLAS, ZUBER CHANTAL, BRUECHER CHRISTOPH, OSTERROTH FRANK, ENGLING ANDRE
Format: Patent
Sprache:eng
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Disclosed is humanized antibody or fragment thereof capable of binding to interleukin-l0 (IL-10), wherein said antibody or fragment thereof comprises a variable light chain comprising the amino acid sequences of CDR 1, CDR2 and CDR3 of the murine antibody B-NI0 variable light chain, and a variable heavy chain comprising the amino acid sequences of CDR1, CDR2 and CDR3 of the murine B-NI0 variable heavy chain, wherein the variable heavy chain further comprises the residues Asn73 and Ser74 of SEQ ID NO: 55 or the corresponding position of the variable heavy chain.